Oppenheimer Bullish on Life Tech's Ion Proton Instrument as Anticipated Launch Nears

Sep 04, 2012

|

NEW YORK (GenomeWeb News) – Anticipating the expected launch of the Life Technologies' Ion Proton benchtop sequencer, Oppenheimer analyst David Ferreiro today estimated 140 placements of the system in 2012 translating to $35.3 million in revenues.

He added that he estimates 200 placements of Ion Proton in 2013 and 300 placements in 2014, which would result in revenues of $75 million and $150.7 million, respectively.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Same Scam, New Tech

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

Gene Therapy for SCID-X1

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

To Guide the Genealogy Search

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

This Week in Nature

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.

Featured White Papers

BlueBee Data Security & Compliance

The Ultimate Guide to Mouse Clinical Trials

Apr

30

Featured Webinar

Novel Methods for Improving De Novo Transcriptome Annotation with Long-Read Transcript Sequencing

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

May

08

Featured Webinar

OncoBEAM ctDNA Testing for Early Response Prediction and Therapy Surveillance in Melanoma and Pancreatic Cancer

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.

Menu